1,2-bis(3,5-dioxopiperazin-1-yl)ethane has been researched along with razoxane in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 10 (47.62) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akutsu, M; Kano, Y; Miura, Y; Narita, T; Sakamoto, S; Suda, K; Suzuki, K | 1 |
| Andoh, T; Ikegami, Y; Ishida, R; Tanabe, K | 1 |
| Andoh, T; Ishida, R; Miki, T; Narita, T; Sato, M; Tanabe, K; Utsumi, KR; Yui, R | 1 |
| Hoshino, A; Inaba, M; Komatsu, T; Narita, T; Takase, M; Tsukagoshi, S; Yaguchi, S | 1 |
| De-Oliveira, MM; Giannotti Filho, O; Joussef, AC; Nakamura, IT | 1 |
| Creighton, AM; el-Hage, AN; Ferrans, VJ; Herman, EH; Witiak, DT | 1 |
| Camerman, A; Camerman, N; Hempel, A | 1 |
| Azuma, Y; Kizaki, H; Onishi, Y | 1 |
| Guo, Y; Xie, X; Xue, Y | 1 |
| Grossmann, V; Kvĕtina, J; Safárová, M; Svoboda, Z | 1 |
| Chadwick, DP; Clark, JR; Ferrans, VJ; Hasinoff, BB; Herman, EH; Zhang, J | 1 |
| Kizaki, H; Onishi, Y | 1 |
| Maehara, Y; Sugimachi, K; Yoshida, M | 1 |
| Arnold, P; Diop, NK; Marusak, RA; Shang, M; Vitellaro, LK | 1 |
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
| Snyder, RD | 1 |
| Jensen, LH; Jensen, PB; Nitiss, JL; Renodon-Cornière, A; Sehested, M; Søkilde, B; Sørensen, TK | 1 |
| Grauslund, M; Jensen, LH; Jensen, PB; Sehested, M; Sorensen, TK | 1 |
| Lu, DY; Lu, TR | 1 |
| Eastmond, DA; Hasegawa, LS; Vuong, MC | 1 |
| Jirkovská, A; Karabanovich, G; Piskáčková, HB; Reimerová, P; Roh, J; Šimůnek, T; Štěrbová-Kovaříková, P | 1 |
1 review(s) available for 1,2-bis(3,5-dioxopiperazin-1-yl)ethane and razoxane
| Article | Year |
|---|---|
Antimetastatic activities and mechanisms of bisdioxopiperazine compounds.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Transformed; Fibrinogen; Humans; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Razoxane | 2010 |
20 other study(ies) available for 1,2-bis(3,5-dioxopiperazin-1-yl)ethane and razoxane
| Article | Year |
|---|---|
The effects of ICRF-154 in combination with other anticancer agents in vitro.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cell Division; Cell Line; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Leukemia-Lymphoma, Adult T-Cell; Razoxane | 1992 |
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Topics: Antineoplastic Agents; Diketopiperazines; DNA; Piperazines; Razoxane; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1991 |
Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Topics: Cell Cycle; Cell Division; Cell Nucleus; Diketopiperazines; DNA Damage; Humans; Mitosis; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Spindle Apparatus; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1991 |
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Leukemia P388; Leukemia, Experimental; Melanoma, Experimental; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Piperazines; Razoxane; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Intratumor chemotherapy in combination with a systemic antimetastatic drug in the treatment of Lewis-lung carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromans; Injections; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Polymers; Razoxane | 1985 |
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
Topics: Animals; Body Weight; Cricetinae; Daunorubicin; Male; Mesocricetus; Piperazines; Razoxane; Stereoisomerism; Structure-Activity Relationship | 1985 |
Bimolane: structure determination indicates anticancer activity is attributable to ICRF-154.
Topics: Antineoplastic Agents; Models, Molecular; Piperazines; Razoxane; X-Ray Diffraction | 1984 |
bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cycloheximide; Dactinomycin; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Gene Expression Regulation; Male; Mice; Mice, Inbred BALB C; Nucleic Acid Conformation; Piperazines; Razoxane; Thymus Gland; Topoisomerase I Inhibitors | 1994 |
Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis.
Topics: Acute Disease; Adult; Antineoplastic Agents; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Humans; Karyotyping; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Psoriasis; Razoxane; Translocation, Genetic | 1997 |
Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect.
Topics: Administration, Oral; Animals; Cardiovascular Agents; Doxorubicin; Drug Evaluation, Preclinical; Electroencephalography; Female; Heart Diseases; Myometrium; Piperazines; Rats; Rats, Wistar; Razoxane | 1997 |
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Chelating Agents; Diketopiperazines; DNA Topoisomerases, Type II; Doxorubicin; Ethylenediamines; Glycine; Heart; Hydrolysis; Iron; Male; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane | 1997 |
Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle; Cells, Cultured; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Gene Expression Regulation; Heterogeneous Nuclear Ribonucleoprotein A1; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Heterogeneous-Nuclear Ribonucleoproteins; Lymphoma; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Razoxane; Ribonucleoproteins; T-Lymphocytes; Thymus Gland; Topoisomerase II Inhibitors | 1997 |
MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Digestive System; Doxorubicin; Female; Humans; Lethal Dose 50; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Piperazines; Prodrugs; Razoxane; Survival Analysis; Tumor Cells, Cultured | 1999 |
Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity.
Topics: Cardiovascular Agents; Crystallography, X-Ray; DNA; Hydrolysis; Iron; Magnetic Resonance Spectroscopy; Molecular Structure; Razoxane; Solutions; Thermodynamics | 2000 |
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |
Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons.
Topics: Animals; Cell Line; Cricetinae; Cricetulus; DNA Damage; Micronucleus Tests; Molecular Structure; Mutagens; Razoxane; Structure-Activity Relationship; Thiobarbiturates; Topoisomerase II Inhibitors | 2003 |
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Catalysis; Diketopiperazines; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Genetic Complementation Test; Humans; Indoles; Isoindoles; Mutagenesis, Site-Directed; Piperazines; Razoxane; Topoisomerase II Inhibitors; Yeasts | 2003 |
Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Topics: Adenosine Triphosphatases; Amino Acid Substitution; Antigens, Neoplasm; Diketopiperazines; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Humans; Kinetics; Piperazines; Razoxane; Topoisomerase II Inhibitors; Vanadates | 2005 |
A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Chromosome Aberrations; Cytokinesis; Humans; Lymphocytes; Micronucleus Tests; Mutagenicity Tests; Mutagens; Razoxane; Topoisomerase II Inhibitors | 2013 |
UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Chromatography, High Pressure Liquid; Edetic Acid; Myocytes, Cardiac; Piperazines; Rats; Rats, Wistar; Razoxane; Tandem Mass Spectrometry | 2019 |